# BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 Balance Sheet

- Company: BridgeBio Pharma, Inc. (BBIO)
- Period: As of 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 2,161,786,000 US dollars
- **Current assets**: 2,044,606,000 US dollars
- **Non-current assets**: 117,180,000 US dollars
- **Liabilities**: 3,815,291,000 US dollars
- **Current liabilities**: 977,237,000 US dollars
- **Non-current liabilities**: 2,838,054,000 US dollars
- **Shareholders' deficit**: negative 1,652,142,000 US dollars
- **Redeemable convertible noncontrolling interests**: negative 1,363,000 US dollars
- **Noncontrolling interest**: 10,200,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Cash and cash equivalents**: 1,533,363,000 US dollars
- **Accounts receivable, net**: 375,089,000 US dollars
- **Prepaid expenses and other current assets**: 70,944,000 US dollars
- **Inventories**: 59,718,000 US dollars
- **Marketable securities**: 5,492,000 US dollars
- **Equity method investments**: 47,783,000 US dollars
- **Intangible assets, net**: 25,923,000 US dollars
- **Other assets**: 22,686,000 US dollars
- **Operating lease right-of-use assets**: 15,746,000 US dollars
- **Property and equipment, net**: 5,042,000 US dollars
- **2027 Notes, net - 2027 Notes, net**: 548,430,000 US dollars
- **Other current liabilities**: 212,114,000 US dollars
- **Accounts payable**: 88,258,000 US dollars
- **Accrued compensation and benefits**: 66,686,000 US dollars
- **Accrued research and development liabilities**: 55,018,000 US dollars
- **Deferred revenue, current portion**: 4,744,000 US dollars
- **Operating lease liabilities, current portion**: 1,987,000 US dollars
- **Deferred royalty obligations, net**: 884,053,000 US dollars
- **2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes - 2029 Notes, net**: 742,437,000 US dollars
- **2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes - 2033 Notes, net**: 620,533,000 US dollars
- **2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes - 2031 Notes, net**: 566,013,000 US dollars
- **Operating lease liabilities, net of current portion**: 14,645,000 US dollars
- **Deferred revenue, net of current portion**: 8,968,000 US dollars
- **Other long-term liabilities**: 1,405,000 US dollars
- **2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes - 2027 Notes, net**: 0 US dollars
- **Additional paid-in capital**: 2,170,006,000 US dollars
- **Undesignated preferred stock and Series A preferred stock - Series A Cumulative Convertible Participating Preferred Stock**: 942,478,000 US dollars
- **Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of June 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025**: 207,000 US dollars
- **Undesignated preferred stock and Series A preferred stock - Undesignated Preferred Stock**: 0 US dollars
- **Noncontrolling interests**: 10,200,000 US dollars
- **Accumulated deficit**: negative 4,194,163,000 US dollars
- **Treasury stock, at cost; 7,597,172 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025**: negative 580,775,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 95,000 US dollars

### Chart connections

- Assets equal liabilities plus temporary equity plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.

## Key Takeaways

- Debt reached $2.48 B, up 34% from $1.85 B at the last year-end, against $1.53 B of cash.
- Liabilities of $3.82 B outweigh $2.16 B of assets, leaving a stockholders' deficit.
- Cash covers the $588.50 M due within a year about 2.6 times, but the peak year asks $770.72 M.
- Series A preferred stock of $933.90 M, sold in July, carries a 7% dividend that accrues.

## The Unvarnished Truth

### BridgeBio's $1.53 B cash pile was raised, not earned

BridgeBio's cash rose from $570.12 M at the last year-end to $1.53 B on September 30, 2026, and the balance sheet looks like a rescue. Look at where the money came from. In the nine months to September 30, operations used $312.55 M, while financing brought in $1.26 B. The largest pieces were $933.90 M of Series A preferred stock sold in July and $632.50 M of new convertible notes. The company also spent $252.50 M buying back its own common stock in the same period.

Why is debt up while equity sits so deep in deficit? Total debt reached $2.48 B, up 34% from $1.85 B at the last year-end, and the notes due within a year, $548.43 M, now sit in current liabilities. The preferred stock is booked as permanent equity, and its 7% dividend accrues whether or not the board declares it. That accrual added $26.29 M to the loss charged to common shareholders this quarter.

What it means: cash of $1.53 B covers the $588.50 M due within a year about 2.6 times, which looks safe. The peak year asks $770.72 M, and the cash is real but borrowed or sold, not earned. Operating cash flow was negative for the nine months, so every new dollar of cash came from a lender or a buyer of its stock. The equity deficit of $1.65 B says the owners' cushion is already gone. Will cash still outrun the debt coming due after another year of operating outflows?

## Intelligent Insights for Investors

### How much debt does BridgeBio have?

It owed $2.48 B of debt on September 30, 2026, up 34% on its level at the last year-end. Cash on hand of $1.53 B could pay off only part of it.

### Has BridgeBio built up profit over its lifetime or accumulated a deficit?

It has an accumulated deficit of $4.19 B on September 30, 2026, against $3.82 B at the last year-end. A deficit can come from past losses or from dividends and buybacks charged against retained earnings.

## Intelligent Insights for Lenders

### When does BridgeBio's debt come due?

Mostly in the next few years. The repayment schedule totals $2.63 B, and its largest single year carries $770.72 M. Of the schedule, $588.50 M is due within a year, against $1.53 B of cash on hand.

## Intelligent Insights for Employees

### Can BridgeBio cover the bills due within a year?

It looks that way. For each dollar due within a year, it held $2.09 in cash and things expected to become cash on September 30, 2026, against $2.77 at the last year-end. Inventory and customer bills count here, so the cover is only as good as how quickly they are sold or collected.
